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In this issue of Cancer Cell, Hatley et al., by using several tour-de-force in vivo approaches, reported a
miR-21-mediated oncogenic pathway through inhibition of negative regulators of the Ras/MEK/ERKpathway
and inhibition of apoptosis in lung cancers models. Targeting miR-21 could be a promising therapeutic
strategy in lung cancers.Understanding MicroRNAs—from
Eppendorf’s Tubes to Mice
and Finally to Humans
The discovery at the beginning of this
decade that the few previously cloned
tiny, worms-related short hairpin RNAs
named microRNAs (miRNAs) are actually
members of a very large class of genes
expressed in the majority of metazoa
organisms and important in any type
of biological process took the scientific
community by surprise (Ambros, 2008).
The knowledge about miRNA functions
and abnormalities accumulated since
could create a mi-Revolution in the way
the diagnosis, prognosis, and therapy
for common diseases, including cancer,
will be performed in the near future.
MicroRNA expression profiling of human
tumors has identified signatures associ-
ated with initiation and progression, diag-
nosis, staging, prognosis, and response
to treatment (Croce, 2009). Most of the
knowledge was obtained from studies
performed in vitro in cell lines or in bulk
tissue from patients, and therefore, what
is needed actually are strong in vivo
evidences that miRNAs are involved in
signaling pathways important in normal
cell homeostasis that are significantly
deregulated in human diseases. The
miRNAs to be exploited for the develop-
ment of useful clinical markers and of
new miRNA-based cancer therapies will
be the ones proved to have a causal role.
MiR-21 Is the Most Significantly
Overexpressed miRNA in Solid
Cancers, including Lung
The research reported byOlson’s group in
this issue is important for several reasons
(Hatley et al., 2010). First, it addressesa significant health problem. Despite the
rapidly development of tumor markers
and therapeutic agents, non-small-cell
lung cancer (NSCLC), which account
for 80% of lung cancers, is the major
leading cause of cancer-related deaths
and the median survival of patients is still
less than 1 year. There is, therefore, a clear
need for early detection and identification
of therapeutic targets and easy-to-test
prognostic markers to optimize and per-
sonalize the diagnosis and treatment of
lung cancer.
Second, the authors targeted the
most significantly deregulated miRNA in
human cancers. In the largest report on
miRNA expression in human cancers,
Volinia and colleagues identified miR-21
as the most differentially expressed
miRNA in 31 types of solid cancers by
comparing 2532 cancer samples versus
806 corresponding normals (Volinia et al.,
2010). This is not a simple quantitative
finding, given thatmiR-21 overexpression
in NSCLC was associated with tumor
aggressiveness and overall survival
(Yanaihara et al., 2006).
Finally and importantly, despite the
large amount of published data in human
samples, all the previous reports showing
the oncogenic activity ofmiR-21 including
high proliferation, low apoptosis, and high
invasion and metastasis potential have
been limited to in vitro assay. The report
by Hatley et al. (2010) revealed for the first
time a miR-21 oncogenic pathway in vivo
by using gain-of-function transgenic mice
and loss-of-function knockout mice of
miR-21 allele in combination with the
K-rasLA2 mouse model of NSCLC (CAG-
miR-21; K-rasLA2 and the miR-21/;
K-rasLA2, respectively). This was a wiselyCancer Cell 18, Seselected combination of crossings that
pay back in a great way the hard work
required for performing these experi-
ments.
An In Vivo Autoregulatory Loop
between Two Oncogenes—miR-21
and RAS
The main finding, although not a great
surprise at this point, was that miR-21
act as a tumor promoter. miR-21 overex-
pression in the CAG-miR-21; K-rasLA2
mice enhanced the incidence of all tumor
grades without an increase in the rate of
conversion from adenoma to adenocarci-
noma, whereas miR-21 deletion in the
miR-21/; K-rasLA2 mice suppressed
formation of all stages of lung tumorigen-
esis, reducing the number of hyperplastic
lesions and adenomas with no adenocar-
cinomas occurrence.
Another important finding is related to
the identification of a multiplayer molec-
ular network involved in proliferation and
apoptosis (Figure 1). Previously published
studies demonstrated that a number of
targets formiR-21 are tumor suppressors
including TPM1, PDCD4, and PTEN.
In addition, other targets including mas-
pin, the apoptosis regulator BCL-2, the
antiproliferative BTG2, and the sprouty
homolog genes SPRY1 and SPRY2 have
been validatedmainly in vitro (for a review,
see Krichevsky and Gabriely, 2009).
The authors hypothesized that increased
miR-21 enhanced the Ras signaling path-
way by inhibiting antagonists of the Ras/
MEK/ERK pathway. They confirmed that
tumors from CAG-miR-21; K-rasLA2 mice
have decreased expression of Spry1,
Spry2, and Btg2 protein compared to
K-rasLA2 tumors resulting in theptember 14, 2010 ª2010 Elsevier Inc. 203
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Figure 1. TheMolecularMechanism InvolvingmiR-21 and the Clinical Significance ofmiR-21
Overexpression in Lung Cancers
The left panel represents the complex mechanism reported by Hatley and colleagues (‘‘the perfection’’ of
miR-21 function), whereas the right panel indicates the main clinical applications (that transform miR-21
‘‘destructive’’ potential to a clinically useful potential). The gene names are as provided in the NCBI data-
base at http://www.ncbi.nlm.nih.gov/gene.
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The authors also evaluated the target for
miR-21 involved in apoptosis and found
that miR-21 overexpression in CAG-miR-
21; K-rasLA2 mice reduced apoptosis.
The targets involved in apoptosis includ-
ing Apaf1, Pdcd4, RhoB, and the Fas
ligand Faslg in tumors from CAG-
miR-21; K-rasLA2 mice were decreased.
A take-home message from this research
is that not all the targets shown by in vitro
experiments have the same relevance
in vivo. Good ways to identify such rele-
vant interaction are either the use of
mouse models or the identification of
negative expression correlations in clin-
ical samples with high purity of tumor
cells.Future Perspectives—Therapeutic
Targeting ofmiR-21
At the center of a very complicated
molecular network, miR-21 can be
exploited for therapeutic purposes. The
authors initiated this investigation by
discovering the fact that miR-21 deletion
can sensitize cells to DNA-damaging
chemotherapy and its overexpression
reduces consequent apoptosis. This
report comes just in time, as Frank Slack’s
group reported on the use of Cre and
Tet-off technologies to generate trans-
genic mice conditionally expressing
miR-21 (Medina et al., 2010). These mice204 Cancer Cell 18, September 14, 2010 ª20developed a pre-B cell lymphoid-like
phenotype and, importantly, tumors re-
gressed completely in a few days when
miR-21 was suppressed. Such results
suggest not only that that miR-21 has
genuine oncogenic activity but also that
due to oncomiR addiction, suppression
of this activity is enough for a potential
therapeutic intervention.Questions, Questions, Questions.
As all good science, the research by
Olson group raises intriguing questions.
For example, why the global expression
ofmiR-21 did not induce tumors, whereas
conditionally overexpression does? The
first in vivo proof that a single miRNA
can cause cancer came from a B cell-
specific miR-155 transgenic mouse
that developed B cell lymphoproliferative
disease shortly after birth (reproducing
the phenotype of the human leukemias
where miR-155 is highly expressed)
generated by Croce’s group (Costinean
et al., 2006). Therefore, apparently the
tissue-specific expression of miRNAs is
the way to induce directly tumor forma-
tion. Also, is the reduced incidence of
thymic lymphoma the only explanation
why the survival of the CAG-miR-21;
K-rasLA2 mice was not significantly
decreased in spite of significantly
increase in the tumors number (and
consequently total tumor area) when10 Elsevier Inc.compared with the K-rasLA2 mice? Did
other unknown yet genetic elements
(maybe other tissue-restricted noncoding
RNAs or other regulatory elements) influ-
ence the tissue expression and natural
history and subsequently survival? Last
but not least, how should the therapeutic
downregulation of miR-21 be achieved?
Antagomirs and other nucleic acids-
based RNA inhibition approaches were
reported. Another option not fully
explored yet could be the SMIRs (small
molecules that targets miRNAs) (Zhang
et al., 2010). The advantage for using
SMIRs is the availability of toxicity and
the biodistribution studies in large pri-
mates that were already done for many
of the small molecules in the past. There-
fore the path to clinical application is
shorter if a specific miRNA target is found.
The first experimentally proof for this
come exactly from a miR-21 study, as
Gumireddy and colleagues identified
diazobenzene and its derivates as effec-
tive inhibitors of miR-21 (Gumireddy
et al., 2008). On the basis of the in vivo
study of Olson’s group, successful inhibi-
tion of miR-21 by innovative drug thera-
pies in NSCLC patients is several steps
closer now and this is great news for
both clinicians and patients!ACKNOWLEDGMENTS
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